Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822242 | 0.89 | TSHR (0.55) | TSHRALDH1A1LMNAACHEKIF11 | |
| SCHEMBL17943229 | 0.85 | TSHR (0.48) | TSHRALDH1A1LMNAACHEALOX12 | |
| SCHEMBL1108511 | 0.84 | TSHR (0.65) | TSHRALDH1A1KIF11CA1CA2 | |
| SCHEMBL822102 | 0.82 | NFE2L2 (0.44) | TSHRALDH1A1ACHEKIF11MEN1 | |
| SCHEMBL23894326 | 0.81 | KIF11 (0.44) | TSHRALDH1A1LMNAACHEALOX12 | |
| SCHEMBL9290946 | 0.81 | ESR1 (0.48) | TSHRALDH1A1LMNAACHEALOX12 | |
| SCHEMBL11349635 | 0.81 | KIF11 (0.44) | TSHRALDH1A1LMNAACHEALOX12 | |
| SCHEMBL2622748 | 0.79 | CYP19A1 (0.47) | TSHRALDH1A1ACHEKIF11MEN1 | |
| SCHEMBL2631997 | 0.79 | KIF11 (0.47) | TSHRALDH1A1LMNAACHEALOX12 | |
| SCHEMBL9632111 | 0.79 | TSHR (0.57) | TSHRALDH1A1LMNAACHEALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| EP-2220083-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8821617-B2 | Polyimide-co-polybenzoxazole copolymer, preparation method thereof, and gas separation membrane comprising the same | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, HANYANG UNIVERSITY (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8821617-B2 | Polyimide-co-polybenzoxazole copolymer, preparation method thereof, and gas separation membrane comprising the same | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, HANYANG UNIVERSITY (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-7311890-B2 | Process for the production of fluorinated organic compounds and fluorinating agents | DAIKIN INDUSTRIES, LTD. (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7311890-B2 | Process for the production of fluorinated organic compounds and fluorinating agents | DAIKIN INDUSTRIES, LTD. (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7311890-B2 | Process for the production of fluorinated organic compounds and fluorinating agents | DAIKIN INDUSTRIES, LTD. (JP) | 2007-12-25 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20040245505-A1 | Process for the production of fluorinated organic compounds and fluorinating agents | DAIKIN INDUSTRIES, LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
| US-6784327-B2 | ORGANIC COMPOUNDS HAVING HYDROGEN ATOMS, WHICH SERVE AS STARTING MATERIALS, ARE FLUORINATED USING IF5 | DAIKIN INDUSTRIES, LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030176747-A1 | Process for the production of fluorinated organic compounds and fluorinating agents | DAIKIN INDUSTRIES, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| CN-1436159-A | Processes for production of fluorinated organic compounds and fluorinating agent | DAIKIN IND LTD (JP) | 2003-08-13 | — | — | CN | disclosed |
| EP-1304316-A1 | PROCESSES FOR THE PRODUCTION OF FLUORINATED ORGANIC COMPOUNDS AND FLUORINATING AGENTS | Daikin Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040245505-A1 | Process for the production of fluorinated organic compounds and fluorinating agents | PFAS, AFF4, AFF1 | TSHR 2577/4885ALDH1A1 1019/4885LMNA 2705/4885 |
| US-20030176747-A1 | Process for the production of fluorinated organic compounds and fluorinating agents | PFAS, AFF4, AFF1 | TSHR 2577/4885ALDH1A1 1019/4885LMNA 2705/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | TSHR 1139/4885ALDH1A1 4697/4885LMNA 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.